What is Arzeda?
Arzeda operates at the vanguard of the bioeconomy, utilizing a sophisticated computational platform to engineer proteins that nature has not yet evolved. By integrating lab automation with high-throughput machine learning, the firm enables the rapid development of sustainable products that serve the diagnostics, pharmaceutical, and industrial sectors. Arzeda's market position is defined by its ability to bridge the gap between theoretical protein design and commercial-scale manufacturing, effectively transforming biological research into tangible, high-value industrial assets.
How much funding has Arzeda raised?
Arzeda has raised a total of $91.7M across 6 funding rounds:
Series A
$15.2M
Debt
$350K
Debt
$599K
Series B
$33M
Other Financing Round
$38M
Stock/Share Issuance
$4.5M
Series A (2017): $15.2M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Debt (2021): $599K supported by PPP
Series B (2022): $33M featuring Bioeconomy Capital, Circulate Capital, Bunge Ventures, Conti Ventures, UMI, Casdin Capital, Lewis & Clark Agrifood, and OS Fund
Other Financing Round (2024): $38M backed by Sofinnova Partners, Bunge Ventures, and Sucden
Stock/Share Issuance (2025): $4.5M, investors not publicly disclosed
Key Investors in Arzeda
Bioeconomy Capital
Bioeconomy Capital is an early-stage venture capital firm that specializes in companies that are laying the foundation for the rapidly expanding bioeconomy.
Circulate Capital
Circulate Capital is a leading investment management firm focused on the circular economy, partnering with global brands and institutional investors to fund sustainable initiatives.
Casdin Capital
Casdin Capital brings a deep understanding, expertise and long-term perspective to financing the next generation of life science innovation.
What's next for Arzeda?
With this latest capital injection, Arzeda is well-positioned to accelerate its R&D pipeline and expand its footprint within the global supply chain. The strategic focus will likely shift toward deepening partnerships with industrial leaders to integrate its protein design capabilities into existing manufacturing workflows. As the company scales, the emphasis will remain on enhancing the efficiency of its computational engine, thereby reducing the time-to-market for novel, sustainable materials and therapeutics. This trajectory suggests a long-term commitment to setting the standard for the next generation of bio-based industrial solutions.
See full Arzeda company page
